Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002080 · ClinicalTrials.gov registry record · NA

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

A NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pharmacia.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002080 is a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection that has completed, run by Pharmacia. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002080, a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, has completed, sponsored by Pharmacia.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin. Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts = or \< 200.

Interventions

  • DRUG Rifabutin

Study Locations (1)

Pennsylvania

  • PACT - Saint Davids

Trial Details

FieldValue
Phase NA

Sponsor

Pharmacia

7 total trials

What the Registry Record Tells You About NCT00002080

The ClinicalTrials.gov registry entry for NCT00002080 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmacia, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Rifabutin is the first listed.

NCT00002080 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00002080 about?

NCT00002080 is a clinical study titled "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study". Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin. Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients...

What is the current status of trial NCT00002080?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002080 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection.

What interventions are being tested in trial NCT00002080?

The interventions under investigation include: Rifabutin (DRUG).

Who is sponsoring clinical trial NCT00002080?

This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002080 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.